Genentech/OSI's Tarceva Will Be Detailed Alongside Herceptin

Tarceva approval comes just three-and-a-half months after application is completed and more than two months ahead of review deadline. Genentech and OSI will begin detailing the non-small cell lung cancer product immediately.